Needham & Company LLC Issues Positive Forecast for GH Research (NASDAQ:GHRS) Stock Price

GH Research (NASDAQ:GHRS) had its price target hoisted by Needham & Company LLC from $31.00 to $32.00 in a report released on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Needham & Company LLC’s price target indicates a potential upside of 110.94% from the company’s current price.

Other equities analysts also recently issued research reports about the stock. TD Cowen reiterated a “buy” rating on shares of GH Research in a research note on Monday, January 5th. Wolfe Research set a $39.00 target price on GH Research in a report on Tuesday, January 6th. Guggenheim restated a “buy” rating and set a $29.00 price target on shares of GH Research in a research note on Monday, January 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of GH Research in a research note on Thursday, January 22nd. Finally, Royal Bank Of Canada increased their price objective on GH Research from $33.00 to $40.00 and gave the company an “outperform” rating in a report on Friday, January 23rd. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, GH Research has an average rating of “Moderate Buy” and a consensus target price of $39.13.

GH Research Price Performance

Shares of NASDAQ:GHRS opened at $15.17 on Friday. The firm’s 50-day moving average is $15.38 and its two-hundred day moving average is $14.21. GH Research has a 1 year low of $7.98 and a 1 year high of $19.51. The firm has a market capitalization of $789.26 million, a PE ratio of -20.50 and a beta of 1.00.

GH Research (NASDAQ:GHRS) last announced its earnings results on Thursday, March 5th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.06. Analysts expect that GH Research will post -0.8 EPS for the current fiscal year.

Hedge Funds Weigh In On GH Research

A number of large investors have recently bought and sold shares of GHRS. Barclays PLC boosted its holdings in shares of GH Research by 63.4% in the fourth quarter. Barclays PLC now owns 2,118 shares of the company’s stock valued at $27,000 after acquiring an additional 822 shares in the last quarter. Osaic Holdings Inc. lifted its position in GH Research by 63.6% in the second quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock valued at $75,000 after purchasing an additional 2,400 shares during the period. Jefferies Financial Group Inc. boosted its holdings in GH Research by 0.4% in the 4th quarter. Jefferies Financial Group Inc. now owns 712,300 shares of the company’s stock valued at $9,046,000 after purchasing an additional 2,988 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in GH Research during the 4th quarter worth approximately $38,000. Finally, JPMorgan Chase & Co. purchased a new position in shares of GH Research during the 2nd quarter worth approximately $79,000. Hedge funds and other institutional investors own 56.90% of the company’s stock.

Key GH Research News

Here are the key news stories impacting GH Research this week:

• Positive Sentiment: Company beat quarterly estimates and reported solid year‑end cash: GH Research reported $0.23 loss per share vs. a consensus -$0.29 (better-than-expected), completed and presented Phase 2b GH001 data, obtained FDA clearance to begin U.S. clinical investigation, and ended 2025 with $280.7M in cash and marketable securities. GH Research Reports Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Broker support and price‑target action: HC Wainwright reaffirmed a Buy and market commentary published this week included a $70 price target, which is a materially higher target than the current share price and provides bullish analyst support. GH Research (NASDAQ:GHRS) Price Target Raised to $70.00
• Positive Sentiment: Longer‑term estimate improvement: HC Wainwright nudged its FY2029 EPS estimate slightly better (from -$1.12 to -$1.02), signalling some incremental optimism on longer‑horizon economics. (Source: HC Wainwright research notes)
• Neutral Sentiment: Short interest data is effectively meaningless/noisy right now — reported short interest showed 0 shares (with NaN change), implying no actionable short‑interest signal given the data anomalies and very low days‑to‑cover figure.
• Negative Sentiment: Analyst cuts to near‑ and medium‑term EPS: HC Wainwright lowered several forecasts (Q4 2025, FY2025, FY2026, FY2027 and FY2028 EPS were revised lower), which weakens near‑term profitability expectations and helps explain downward pressure despite balanced positives above. HC Wainwright Comments on GH Research FY2030 Earnings

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.